JACOBS LEVY EQUITY MANAGEMENT, INC

Position in LGND — Ligand Pharmaceuticals Inc

CIK 884414 FLORHAM PARK, NJ

Position in LGND

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$4,098,614

-$19,866,764 QoQ

Shares Held

20,529

-83.8% QoQ

Ownership

0.102%

of shares outstanding

% of Portfolio

0.02%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2023

9 quarters on record

Voting authority Sole 68.90739928881095.ToString("F0")% Shared 0.ToString("F0")% None 31.09260071118905.ToString("F0")%

Healthcare · as of Mar 31, 2026

JACOBS LEVY EQUITY MANAGEMENT, INC holds $705,903,019 across 86 Biotechnology names. LGND ranks #25 (0.6% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc.	214,160	$165,468,582
2	INCY	Incyte Corp	1,717,978	$161,696,089
3	ALNY	Alnylam Pharmaceuticals, Inc.	212,204	$70,211,937
4	HALO	Halozyme Therapeutics, Inc.	789,429	$51,020,796
5	RARE	Ultragenyx Pharmaceutical Inc.	1,431,071	$29,980,937
6	EXEL	Exelixis, Inc.	425,982	$18,270,367
7	AUPH	Aurinia Pharmaceuticals Inc.	1,097,189	$16,260,340
8	ARVN	Arvinas, Inc.	1,441,521	$15,280,122

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$4,098,614	20,529	-83.8%	Shares	Sole	2026-05-15
2025-12-31	$23,965,378	126,754	-0.7%	Shares	Sole	2026-02-13
2025-09-30	$22,618,829	127,689	-21.6%	Shares	Sole	2025-11-17
2025-06-30	$18,508,240	162,810	+3.6%	Shares	Sole	2025-08-14
2025-03-31	$16,526,010	157,181	+964.8%	Shares	Sole	2025-05-15
2024-03-31	$1,079,102	14,762	-27.2%	Shares	Sole	2024-05-15
2023-12-31	$1,448,326	20,279	-16.7%	Shares	Sole	2024-02-14
2023-09-30	$1,457,973	24,332	+532.8%	Shares	Sole	2023-11-17
2023-03-31	$282,838	3,845	—	Shares	Sole	2023-05-15
No filing history on record for this holder in this stock.